Transcranial Magnetic Stimulation (TMS): Clinical Reference
Transcranial magnetic stimulation is a non-invasive brain stimulation technique cleared by the FDA for treating major depressive disorder and several other psychiatric conditions. It works by delivering focused magnetic pulses through the skull to modulate neural activity in targeted cortical regions — no surgery, no anesthesia, no seizure induction. For patients who have cycled through antidepressants without relief, TMS often represents the first genuinely different treatment option they encounter. This page covers how TMS is defined clinically, the mechanism behind the pulses, the conditions for which it is used, and the evidence-based criteria that inform when it is and is not appropriate.
Definition and scope
TMS delivers brief, rapidly changing magnetic fields through a coil placed against the scalp. Those fields induce electrical currents in underlying cortical neurons — enough to depolarize cells and alter local circuit activity — without any electrodes, incisions, or direct electrical contact with the brain. The FDA first cleared TMS for treatment-resistant depression and mood disorders in 2008, and subsequent clearances have extended its labeled use to include obsessive-compulsive disorder, migraines, smoking cessation (as an adjunct), and anxious depression.
The term "treatment-resistant" carries a specific clinical meaning here. Most TMS protocols are indicated for major depressive disorder in adults who have not responded to at least one adequate antidepressant trial — meaning a drug at a therapeutic dose for a sufficient duration (typically 4–6 weeks minimum). That single-failure threshold is notably lower than the standard applied to electroconvulsive therapy, which generally requires failure of multiple medication trials. TMS therefore sits in the treatment sequence earlier than ECT for many patients.
How it works
The physics are elegant in a quietly counterintuitive way: a magnetic field passes harmlessly through bone and scalp tissue, then induces current only in the conductive neural tissue beneath. The coil generates a magnetic field pulse measuring roughly 1.5 to 2.0 Tesla — comparable in peak strength to an MRI scanner, but delivered in milliseconds rather than continuously.
The standard target for depression treatment is the left dorsolateral prefrontal cortex (DLPFC), a region consistently implicated in mood regulation and executive function research. High-frequency stimulation (10 Hz is common in approved protocols) has an excitatory net effect on cortical neurons, counteracting the hypoactivity observed in this region in depressed patients. Low-frequency protocols (1 Hz) are inhibitory and are used when the clinical goal is to suppress overactive regions — a strategy that appears in some OCD and PTSD applications, where a different coil geometry targets the supplementary motor cortex or medial prefrontal areas.
The three most common protocol types in clinical practice:
- Repetitive TMS (rTMS) — The standard format. Pulses delivered in trains at fixed frequencies over 20–40 minute sessions, typically 5 days per week for 4–6 weeks (approximately 30–36 total sessions in an index course).
- Theta-burst stimulation (TBS) — A compressed protocol delivering bursts of high-frequency pulses nested within a 5 Hz theta rhythm. Intermittent TBS (iTBS) achieves comparable outcomes to rTMS in far less time — as little as 3 minutes per session — and received FDA clearance based on the THREE-D trial published in The Lancet in 2018.
- Deep TMS (dTMS) — Uses an H-coil geometry to reach deeper cortical and subcortical structures. The FDA-cleared Brainsway H-coil system is the primary commercial implementation, and carries separate clearance for OCD treatment.
Common scenarios
TMS is most frequently encountered in outpatient psychiatric settings as a step-up treatment after antidepressant failure. A patient with moderate-to-severe major depressive disorder who has not responded to an adequate trial of an SSRI or SNRI would typically be evaluated for TMS before ECT is considered.
Beyond depression, the clinical picture is expanding. The FDA clearance for OCD — using the dTMS H-coil targeting the medial prefrontal cortex and anterior cingulate — came in 2018, making TMS a meaningful option for patients with OCD who have not responded to first-line treatment (which, per the American Psychiatric Association, means an adequate SSRI trial plus exposure and response prevention therapy). Veterans with PTSD represent another actively researched population, with multiple protocols under clinical investigation targeting distinct neural circuits.
TMS is also used as a maintenance therapy. After an index course produces remission, some patients undergo a maintenance schedule — weekly or biweekly sessions — to prevent relapse, particularly when medication for mental health has proven insufficient or intolerable.
Decision boundaries
TMS is not appropriate for everyone. Absolute contraindications center on metal in or near the head: cochlear implants, aneurysm clips, deep brain stimulators, or any ferromagnetic implant within the magnetic field range creates a safety risk. Patients with a personal history of seizure disorders require careful risk-benefit analysis, since TMS carries a small seizure risk (estimated below 0.1% per session in standard protocols, according to published safety reviews in Brain Stimulation journal).
Comparing TMS to ECT clarifies where each belongs:
| Factor | TMS | ECT |
|---|---|---|
| Anesthesia required | No | Yes (general) |
| Seizure induced | No (adverse event) | Yes (therapeutic mechanism) |
| Memory side effects | Minimal | Significant short-term risk |
| Speed of response | 4–6 weeks | Often 2–3 weeks |
| Severity threshold | Moderate-to-severe | Severe, catatonia, psychotic depression |
| Outpatient-compatible | Yes | Typically not during acute course |
Patients with psychotic features, active suicidal crisis requiring hospitalization, or severe comorbidities may need inpatient care before TMS is viable. TMS is generally considered an elective, scheduled outpatient procedure — not a crisis intervention. Clinicians evaluating candidates typically also review psychiatric history, including any bipolar disorder diagnosis, since stimulating the left DLPFC carries a theoretical risk of mood switching in vulnerable individuals, a factor that shapes both protocol selection and monitoring frequency.
The finding a mental health provider process for TMS specifically requires identifying a psychiatrist or clinic with the equipment and trained staff to administer the treatment — availability remains uneven across regions, with urban centers carrying significantly higher concentrations of TMS-equipped practices than rural areas.